Orchestra BioMed Holdings, Inc.
OBIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | -0.65 | -0.13 | -0.97 |
| FCF Yield | -15.61% | -15.12% | -10.22% | -8.96% |
| EV / EBITDA | -2.72 | -5.22 | -8.66 | -8.83 |
| Quality | ||||
| ROIC | -23.94% | -73.19% | -42.85% | -27.56% |
| Gross Margin | 94.31% | 94.50% | 94.93% | 77.08% |
| Cash Conversion Ratio | 0.70 | 0.80 | 0.89 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | -7.85% | -12.17% | -9.01% | -9.28% |
| Free Cash Flow Growth | 4.50% | 6.98% | -22.60% | 0.90% |
| Safety | ||||
| Net Debt / EBITDA | 1.99 | 0.12 | 0.10 | 0.35 |
| Interest Coverage | -39.44 | -536.86 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.13 | 0.25 | 0.33 | 0.34 |
| Cash Conversion Cycle | -14,886.81 | -10,014.33 | -11,093.50 | -7,665.38 |